2022
Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
Dahal P, Simpson J, Abdulla S, Achan J, Adam I, Agarwal A, Allan R, Anvikar A, Arinaitwe E, Ashley E, Awab G, Bassat Q, Björkman A, Borrmann S, Bousema T, Bukirwa H, Carrara V, Corsi M, Cot M, D’Alessandro U, Davis T, Deloron P, Desai M, Dimbu P, Djalle D, Djimde A, Dorsey G, Drakeley C, Duparc S, Edstein M, Espie E, Faiz A, Falade C, Fanello C, Faucher J, Faye B, de Jesus Fortes F, Gadalla N, Gaye O, Gil J, Gilayeneh J, Greenwood B, Grivoyannis A, Hien T, Hwang J, Janssens B, Juma E, Kamugisha E, Karema C, Karunajeewa H, Kiechel J, Kironde F, Kofoed P, Kremsner P, Lee S, Marsh K, Mårtensson A, Mayxay M, Menan H, Mens P, Mutabingwa T, Ndiaye J, Ngasala B, Noedl H, Nosten F, Offianan A, Ogutu B, Olliaro P, Ouedraogo J, Piola P, Plowe C, Plucinski M, Pratt O, Premji Z, Ramharter M, Rogier C, Rombo L, Rosenthal P, Sibley C, Sirima S, Smithuis F, Staedke S, Sutanto I, Talisuna A, Tarning J, Taylor W, Temu E, Thriemer K, Thuy-Nhien N, Udhayakumar V, Ursing J, van Herp M, van Lenthe M, van Vugt M, William Y, Winnips C, Zaloumis S, Zongo I, White N, Guerin P, Stepniewska K, Price R. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal 2022, 21: 106. PMID: 35331243, PMCID: PMC8943927, DOI: 10.1186/s12936-021-03980-z.Peer-Reviewed Original ResearchConceptsDihydroartemisinin-piperaquineDays follow-upFollow-upEfficacy trialsRecrudescent infectionsRisk of recrudescenceAnti-malarial efficacy studiesUncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapyDuration of follow-upPlasmodium falciparum malariaAnti-malarial treatmentMethodsIndividual patient dataFollow-up periodFollow-up time pointsCox regression modelsClinical efficacy trialsTreatment Efficacy TrialData meta-analysisTrial follow-upMalaria recrudescencePiperaquine dosingRecrudescent parasitaemiaFalciparum malariaOptimal follow-up period
2019
Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis
Dahal P, Simpson J, Abdulla S, Achan J, Adam I, Agarwal A, Allan R, Anvikar A, Arinaitwe E, Ashley E, Awab G, Bassat Q, Björkman A, Bompart F, Borrmann S, Bousema T, Broek I, Bukirwa H, Carrara V, Corsi M, Cot M, D’Alessandro U, Davis T, de Wit M, Deloron P, Desai M, Dimbu P, Djalle D, Djimde A, Dorsey G, Doumbo O, Drakeley C, Duparc S, Edstein M, Espie E, Faiz A, Falade C, Fanello C, Faucher J, Faye B, de Jesus Fortes F, Gadalla N, Gaye O, Gil J, Greenwood B, Grivoyannis A, Hamed K, Hien T, Hughes D, Humphreys G, Hwang J, Ibrahim M, Janssens B, Jullien V, Juma E, Kamugisha E, Karema C, Karunajeewa H, Kiechel J, Kironde F, Kofoed P, Kremsner P, Lameyre V, Lee S, Marsh K, Mårtensson A, Mayxay M, Menan H, Mens P, Mutabingwa T, Ndiaye J, Ngasala B, Noedl H, Nosten F, Offianan A, Oguike M, Ogutu B, Olliaro P, Ouedraogo J, Piola P, Plowe C, Plucinski M, Pratt O, Premji Z, Ramharter M, Rogier C, Rombo L, Rosenthal P, Sawa P, Schramm B, Sibley C, Sinou V, Sirima S, Smithuis F, Staedke S, Sutanto I, Talisuna A, Tarning J, Taylor W, Temu E, Thriemer K, Thuy N, Udhayakumar V, Ursing J, van Herp M, van Vugt M, Whitty C, William Y, Winnips C, Zongo I, Guerin P, Price R, Stepniewska K. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis. Malaria Journal 2019, 18: 225. PMID: 31277713, PMCID: PMC6612160, DOI: 10.1186/s12936-019-2837-4.Peer-Reviewed Original ResearchConceptsPlasmodium falciparum malariaFollow-up periodCumulative incidence functionFalciparum malariaRisk of recrudescenceUncomplicated Plasmodium falciparum malariaAntimalarial drug trialsLog-rank testProportion of patientsKaplan-Meier (K-M) methodK-M curvesData meta-analysisK-M methodSub-distribution hazard modelCause-specific Cox modelsAntimalarial trialsIndividual participant data meta-analysisParticipant data meta-analysisAntimalarial efficacyAbsolute overestimationKaplan-MeierFollow-upPrimary infectionTransmission settingsConclusionsThe 1
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, ROSENTHAL P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrials